CoChat
Cited by 7

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Mechanism of dimer selectivity and binding cooperativity of BRAF inhibitors

Clayton, Joseph, Romany, Aarion, Matenoglou, Evangelia, Gavathiotis, Evripidis, Poulikakos, Poulikos I, Shen, Jana · 2025 · eLife

Published version of a preprint

Abstract

Aberrant signaling of BRAF V600E is a major cancer driver. Current FDA-approved RAF inhibitors selectively inhibit the monomeric BRAF V600E and suffer from tumor resistance. Recently, dimer-selective and equipotent RAF inhibitors have been developed; however, the mechanism of dimer selectivity is poorly understood. Here, we report extensive molecular dynamics (MD) simulations of the monomeric and dimeric BRAF V600E in the apo form or in complex with one or two dimer-selective (PHI1) or equipotent (LY3009120) inhibitor(s). The simulations uncovered the unprecedented details of the remarkable allostery in BRAF V600E dimerization and inhibitor binding. Specifically, dimerization retrains and shifts the αC helix inward and increases the flexibility of the DFG motif; dimer compatibility is due to the promotion of the αC-in conformation, which is stabilized by a hydrogen bond formation between the inhibitor and the αC Glu501. A more stable hydrogen bond further restrains and shifts the αC helix inward, which incurs a larger entropic penalty that disfavors monomer binding. This mechanism led us to propose an empirical way based on the co-crystal structure to assess the dimer selectivity of a BRAF V600E inhibitor. Simulations also revealed that the positive cooperativity of PHI1 is due to its ability to preorganize the αC and DFG conformation in the opposite protomer, priming it for binding the second inhibitor. The atomically detailed view of the interplay between BRAF dimerization and inhibitor allostery as well as cooperativity has implications for understanding kinase signaling and contributes to the design of protomer selective RAF inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7554/elife.95334.4

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 40

  1. Adamopoulos, 2021, Exploiting allosteric properties of raf and mek inhibitors to target therapy-resistant tumors driven by oncogenic BRAF signaling, Cancer Discovery, 11, 1716, 10.1158/2159-8290.CD-20-1351 · DOI
  2. Brooks, 2009, CHARMM: The biomolecular simulation program, Journal of Computational Chemistry, 30, 1545, 10.1002/jcc.21287 · DOI · Paper page
  3. Case, 2020, AMBER 2020
  4. Clayton J, Shen J. 2024. RAF. Software Heritage. swh:1:rev:8f2e939ee7f4b42583b62cb09d6a0295ae327280. https://archive.softwareheritage.org/swh:1:dir:fc9557b9c32c386d652a37124cab072f9c9f16ce;origin=https://github.com/JanaShenLab/RAF;visit=swh:1:snp:bdd193c7b074e905ca876c3592a6c01c9b5aba54;anchor=swh:1:rev:8f2e939ee7f4b42583b62cb09d6a0295ae327280.
  5. Cook, 2021, Inhibition of RAF dimers: it takes two to tango, Biochemical Society Transactions, 49, 237, 10.1042/BST20200485 · DOI
  6. Cotto-Rios, 2020, Inhibitors of BRAF dimers using an allosteric site, Nature Communications, 11, 10.1038/s41467-020-18123-2 · DOI
  7. Darden, 1993, Particle mesh Ewald: An N ⋅log(N) method for Ewald sums in large systems, The Journal of Chemical Physics, 98, 10089, 10.1063/1.464397 · DOI · Paper page
  8. Feller, 1995, Constant pressure molecular dynamics simulation: the Langevin piston method, The Journal of Chemical Physics, 103, 4613, 10.1063/1.470648 · DOI · Paper page
  9. Grasso, 2016, Chemically linked vemurafenib inhibitors promote an inactive BRAFV600E conformation, ACS Chemical Biology, 11, 2876, 10.1021/acschembio.6b00529 · DOI
  10. Harris, 2022, GPU-accelerated all-atom particle-mesh ewald continuous constant pH molecular dynamics in amber, Journal of Chemical Theory and Computation, 18, 7510, 10.1021/acs.jctc.2c00586 · DOI
  11. Hatzivassiliou, 2010, RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth, Nature, 464, 431, 10.1038/nature08833 · DOI · Paper page
  12. Henderson, 2020, Assessment of proton-coupled conformational dynamics of SARS and MERS coronavirus papain-like proteases: Implication for designing broad-spectrum antiviral inhibitors, The Journal of Chemical Physics, 153, 10.1063/5.0020458 · DOI
  13. Henderson, 2022, A guide to the continuous constant ph molecular dynamics methods in amber and CHARMM, Living Journal of Computational Molecular Science, 4, 10.33011/livecoms.4.1.1563 · DOI
  14. Hopkins, 2015, Long-time-step molecular dynamics through hydrogen mass repartitioning, Journal of Chemical Theory and Computation, 11, 1864, 10.1021/ct5010406 · DOI · Paper page
  15. Jorgensen, 1983, Comparison of simple potential functions for simulating liquid water, The Journal of Chemical Physics, 79, 926, 10.1063/1.445869 · DOI · Paper page
  16. Kanev, 2021, KLIFS: an overhaul after the first 5 years of supporting kinase research, Nucleic Acids Research, 49, D562, 10.1093/nar/gkaa895 · DOI · Paper page
  17. Karoulia, 2016, An integrated model of RAF inhibitor action predicts inhibitor activity against oncogenic BRAF signaling, Cancer Cell, 30, 485, 10.1016/j.ccell.2016.06.024 · DOI · Paper page
  18. King, 2006, Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885, Cancer Research, 66, 11100, 10.1158/0008-5472.CAN-06-2554 · DOI · Paper page
  19. Kooistra, 2016, KLIFS: A structural kinase-ligand interaction database, Nucleic Acids Research, 44, D365, 10.1093/nar/gkv1082 · DOI · Paper page
  20. Lavoie, 2013, Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization, Nature Chemical Biology, 9, 428, 10.1038/nchembio.1257 · DOI · Paper page
  21. Lavoie, 2020, ERK signalling: A master regulator of cell behaviour, life and fate, Nature Reviews Molecular Cell Biology, 21, 607, 10.1038/s41580-020-0255-7 · DOI · Paper page
  22. Liao, 2007, Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors, Journal of Medicinal Chemistry, 50, 409, 10.1021/jm0608107 · DOI · Paper page
  23. Maier, 2015, ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB, Journal of Chemical Theory and Computation, 11, 3696, 10.1021/acs.jctc.5b00255 · DOI · Paper page
  24. Maloney, 2021, The mechanism of activation of monomeric B-Raf V600E, Computational and Structural Biotechnology Journal, 19, 3349, 10.1016/j.csbj.2021.06.007 · DOI
  25. Möbitz, 2015, The ABC of protein kinase conformations, Biochimica et Biophysica Acta, 1854, 1555, 10.1016/j.bbapap.2015.03.009 · DOI
  26. Monaco, 2021, LXH254, a potent and selective ARAF-Sparing inhibitor of BRAF and CRAF for the treatment of MAPK-driven tumors, Clinical Cancer Research, 27, 2061, 10.1158/1078-0432.CCR-20-2563 · DOI
  27. Peng, 2015, Inhibition of RAF isoforms and active dimers by LY3009120 leads to anti-tumor activities in RAS or BRAF mutant cancers, Cancer Cell, 28, 384, 10.1016/j.ccell.2015.08.002 · DOI · Paper page
  28. Poulikakos, 2010, RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF, Nature, 464, 427, 10.1038/nature08902 · DOI · Paper page
  29. Rajakulendran, 2009, A dimerization-dependent mechanism drives RAF catalytic activation, Nature, 461, 542, 10.1038/nature08314 · DOI · Paper page
  30. Rasmussen, 2023, Allosteric coupling asymmetry mediates paradoxical activation of BRAF by type ii inhibitors, 10.1101/2023.04.18.536450 · DOI
  31. Roe, 2013, PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data, Journal of Chemical Theory and Computation, 9, 3084, 10.1021/ct400341p · DOI · Paper page
  32. Schrödinger LLC. 2015. The pymol molecular graphics system. pYmol. 8. https://pymol.org/.
  33. Thevakumaran, 2015, Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation, Nature Structural & Molecular Biology, 22, 37, 10.1038/nsmb.2924 · DOI · Paper page
  34. Tkacik, 2023, Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib, The Journal of Biological Chemistry, 299, 10.1016/j.jbc.2023.104634 · DOI
  35. Tsai, 2019, How electrostatic coupling enables conformational plasticity in a tyrosine kinase, Journal of the American Chemical Society, 141, 15092, 10.1021/jacs.9b06064 · DOI
  36. Tse, 2016, Exploring molecular mechanisms of paradoxical activation in the BRAF kinase dimers: atomistic simulations of conformational dynamics and modeling of allosteric communication networks and signaling pathways, PLOS ONE, 11, 10.1371/journal.pone.0166583 · DOI
  37. Wallace, 2011, Continuous constant pH molecular dynamics in explicit solvent with pH-based replica exchange, Journal of Chemical Theory and Computation, 7, 2617, 10.1021/ct200146j · DOI · Paper page
  38. Wang, 2004, Development and testing of a general amber force field, Journal of Computational Chemistry, 25, 1157, 10.1002/jcc.20035 · DOI · Paper page
  39. Yao, 2018, Elucidating allosteric communications in proteins with difference contact network analysis, Journal of Chemical Information and Modeling, 58, 1325, 10.1021/acs.jcim.8b00250 · DOI
  40. Zhang, 2021, The mechanism of Raf activation through dimerization, Chemical Science, 12, 15609, 10.1039/D1SC03444H · DOI

Cited by

See all 7

Metadata

Authors
Clayton, J., Romany, A., Matenoglou, E., Gavathiotis, E., Poulikakos, P. I., & Shen, J.
Affiliations
  • Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy
  • Department of Biochemistry, Department of Medicine, Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine
  • Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai
Venue
eLife
Published
2025-02-13
Volume
13
ISSN
2050-084X
Cited by
7
References
5
Language
en
Funders
National Institutes of Health (R01CA256557, R01CA238229)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.